Cannabis sales sky rocket in 2020!

The Now Company may be one of the hottest stocks in the green industry ready to capitalize! In 2020, Americans turned to cannabis in record numbers to deal with the pandemic. A staggering $18 billion worth of the plant's products were purchased, representing a 67% increase over 2019. The industry is thriving and we may soon be seeing federal prohibition come to an end which could send stocks like The Now Company (OTC: NWPN) blasting off. The Federal government can't stick its head in the sand much longer and ignore the immense profit opportunity of the industry and the demands of the people. The Now Company (OTC: NWPN) especially looks poised to separate itself from the rest as the company is well positioned to capitalize on the emerging opportunities resulting from the need for more research studies of the plant, product testing, hemp cultivation and production, product development, and education. The company is also aiming for an FDA approval on a CBD medicine that could become one of the biggest acquisition targets on Wall Street! Learn why NWPN may quickly emerge in America's cannabis "Green Rush" as the next big winner! Our Exclusive Report On: [( In the midst of growing worldwide interest in medicinal cannabis, NWPN is lighting up on Wall Street with enormous profit potential ahead! Shares of NWPN were as high as $0.025 in September and were as low as $0.0041 in August before they hit that high. This was a move of over 500% in only weeks! Could a repeat breakout be on the horizon? Traders hunt high and low to find the next Amazon of the arena and with how much NWPN has going on, this is an exciting story to see unfold. Joe Biden is the next president of the U.S. and he and Vice President candidate Kamala Harris have been vocal on decriminalizing marijuana on a federal level. A Democratic administration could help the legal marijuana arena explode even more than it has been. Especially with the Democrats now controlling the Senate. Excitingly while more than three out of four Democrats support cannabis legalization, recent polls have found that slightly more than half of Republican voters now support it also. Legalizing cannabis is an increasingly bipartisan, national issue. The public awareness of CBD and its many natural benefits is exploding and CBD products are flooding the market. As CBD becomes legal and more available throughout the US, increased government regulation is inevitable! This could bode very well for NWPN, a bio-pharmaceutical research company focused on the research, education and production of Scientific-Grade Cannabidiol (CBD) from hemp and Tetrahydrocannabinol (THC) to be used for medicinal purpose, while focusing on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its acquired assets, the company is seeking to invest in its businesses associated with the growing, marketing, research and development, training, distribution and retail sale of scientific-grade medicinal cannabis, both in the United States and Canada. This includes, but is not limited to, food, paper, and textiles derived from Hemp. It was with the 2018 Farm Bill that was passed in December 2018, that industrial hemp in the United States became federally legalized. This means that hemp is no longer regulated as an illegal substance under the US Justice Department and this is greatly benefiting the CBD industry. According to New Frontier Data: China led all countries with nearly $1.2 billion USD in hemp sales in 2018, followed by the United States ($1.0 billion), Europe ($980 million) and South and Central America ($220 million). The U.S. market is positioned to grow under the 2018 Farm Bill, with an estimated $2.6 billion projected in sales by 2022, with $1.3 billion in sales estimated for hemp-derived CBD products by 2022! According to the National Retail Federation, the CBD industry grew in customer demand by a whopping 700 percent in 2019. CBD sales are also expected to reach $4 billion dollars by 2023 says the Nutrition Business Journal. NWPN additionally provides Credible Scientific Research Data to the heavily regulated medical and recreational marijuana industries - currently one of the fastest growing industries in North America. On November 19, 2019, The FDA warned 15 companies for illegally selling various products containing cannabidiol as the agency details safety concerns. Violations included marketing unapproved new human and animal drugs, selling CBD products as dietary supplements, and adding CBD to human and animal foods. These are concerning issues that take place in the marijuana industry and through the company's research, NWPN will address such safety concerns by performing rigorous testing of CBD compounds. By publishing a scientific white paper based on the study, it will additionally allow the FDA to review the information and have credible data to make concrete rulings. While the industry is big, safety concerns are still prevalent creating a demand for the type of research NWPN is involved with! Two-thirds of Americans now say the use of marijuana should be legal, reflecting a steady increase over the past decade, according to a new Pew Research Center survey. More consumers are turning to marijuana with marijuana sales hitting records in many states even amid the COVID-19 pandemic. Across the country, sales are sky high in states where legal cannabis has been declared “essential medicine” during state shutdowns. Last year marijuana sales in the USA trumped 2019 sales as consumers turned to the plant during the pandemic. It's obvious this is a very big and growing industry and CBD research is needed. NWPN has signed a joint venture with Hollywood Diagnostics Center to perform neurological studies using state-of-the-art imaging technology to measure brain activity by detecting changes associated with blood flow when CBD compounds are introduced to the human body. Hollywood Diagnostics Center is a leader in the medical diagnostics field while performing over 30,000 diagnostic procedures annually! The goal of the imaging data analysis is to detect correlations between brain activation in subjects when either non-tasked or tasked activities are performed during the scan with CBD compounds present. You can read more here: [ NWPN's long term goal is to have an FDA approved medicine that focuses on nausea and other ailments. Due to the FDA approval, it will be available for pharmacies to dispense, and will be on the approved list for insurance companies to pay for. Ultimately, the company will pursue patenting the compound on a molecular level, similar to Pfizers patent on the drug, Viagra. Nausea and vomiting are not diseases, but they are symptoms of many conditions such as: Motion sickness or seasickness. Early stages of pregnancy (nausea occurs in approximately 50%-90% of all pregnancies; vomiting in 25%-55%). This makes the market for an anti-nausea medicine significant! One reason to closely follow NWPN is because of big pharma... Big pharma is definitely recognizing the very lucrative opportunity when it comes to medicinal marijuana. Cannabis is inexpensive to produce, and with the right policies, there could be widespread access to those in need, which disrupts the traditional marketplace. A recent report found that Big Pharma stands to lose as much as $4 billion per year if medical marijuana became legal in all 50 states. The information is based off a study from 2016 by the University of Georgia, which found that states with legalized medicinal cannabis had less Medicare prescriptions than those where it's still illegal. The study found that already pharmaceutical companies are losing $166 million annually on drugs where marijuana is now offered as an alternative. Big pharma will have no choice but to jump onto the cannabis bandwagon if they want to continue capitalizing on patients! GW Pharmaceuticals did and in the summer of 2018, Epidiolex became the first FDA-approved plant-derived cannabinoid medicine available by prescription in the U.S. to treat seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. Epidiolex brought in $104 million in net sales in the fourth quarter and a total of $296 million in 2019 across the globe! Pharmaceutical giants are already preparing for the cannabis revolution and are building connections. Plus with the rise in opioid lawsuits, it may lead to many drug companies looking to cannabinoids in the search for less-addictive pain relievers. This will only further fuel the momentum of the cannabis revolution and these pharma giants could be going on shopping sprees to scoop up smaller players such as NWPN! Many of you may know that there is a growing problem with fossil fuel depletion. As the price at the pumps continue to rise, the law of supply and demand, as well as many top analysts predict our crude oil resources are running out. Crude oil is not a renewable resource, so once it’s gone… well, that's it. This is why hemp biofuel is looking like an attractive alternative and NWPN could soon get recognized for its pilot program for producing derivatives from Industrial Hemp for biodiesel fuel in North Dakota! NWPN has an interest in the Hemp biofuel industry to provide a renewable alternative energy solution. With respect to furtherance of this goal, the company looks to employ advanced chemistry research and technologies to elucidate the biological Hemp molecules to advance quality and effectiveness of the biofuel. North America has absolutely no problem extracting oil from Hemp seeds which the company can subsequently use to make biofuel. The company has currently executed a joint venture in the US for the production of Industrial Hemp for the purpose of biofuel research and production in the State of North Dakota. The Industrial Hemp farming industry is capable of bringing the United States 100% clean, renewable energy! "Our vision is clear, Industrial hemp is perfectly capable of fueling the modern world without displacing food or adding to the Greenhouse effect. We will embrace the research and development of a constant, safe and quality alternative energy. We live on this planet and need to do everything within our power to protect it so future generations can thrive," said CEO Ken Williams. It should be noted that Williams has spent five years leading public companies in the Legal Marijuana Industry, three decades of Advanced Technology Engineering, and as an executive for multi-million-dollar brands! Last January NWPN announced a pilot program for producing derivatives from Industrial Hemp for biodiesel fuel in North Dakota. The NOW Biodiesel Pilot Program forms part of the existing joint venture agreement with Mr. Curtis Johnson, for the cultivation of Industrial Hemp to be grown near Grand Forks, North Dakota. For the 2020 grow season, the pilot program will consist of 400 acres and, upon a successful growing season, the following years will then expand to include over 1000+ acres. NWPN is also aiming to work with both NASA and SpaceX for its research initiatives. Concerning NASA, the company would like to utilize the International Space Station for unique discoveries of how CBD and THC reacts using animal testing. Cells tend to have a different effects in zero gravity. Concerning SpaceX, they are aggressive in taking humans to space, for long extended times, and eventually to Mars. Through the company's research initiatives, the creation of an organic CBD nausea drug would be safe and beneficial for astronauts. The company then announced last September that it has acquired 50% of a trademarked brand that will be used to sell CBD/Marijuana Products. The company remains in talks with a celebrity spokesperson that will be the perfect candidate to market this brand as he is described as an outrageous character. He was a professional athlete as well as a well regarded actor! Ken Williams, CEO of NWPN has stated, "We finally have a signed agreement. We now need this celebrity spokesperson. In case this doesnt come to fruition, I am on the lookout for other interested parties." NWPN additionally announced at the start of October that it will begin to perfect the correct mixture to maximize efficacy for a cbd-infused sports cream to help with muscle aches and stiffness. This will also provide athletes with the ability to recover faster from intense workouts. The ingredients to be included in this cream will consist of, but not be limited to, the following: CBD topical base oil, shea butter, beeswax pellets, or clean beeswax, chopped fine Menthol crystals (to enhance absorption and effect), Eucalyptus essential oil, camphor oil and extracts (mint oil, shiling oil and exotic roots). NWPN is considering marketing and selling this under a brand that they may purchase with a significant social media following. NWPN looks poised to separate itself from all the rest with so many exciting plans... make sure you have the stock on your watchlist! This is a company well positioned to capitalize on the emerging opportunities resulting from the need for more research studies, product testing, hemp cultivation and production, product development, and education. Especially as NWPN's CEO Ken Williams has spent five years leading public companies in the Legal Marijuana Industry, three decades of Advanced Technology Engineering, and as an executive for multi-million-dollar brands! This is looking like a ground-floor situation that may not remain off of Wall Street's radar much longer. The stock was trading around current levels when it soared to over 2 cents last year.... The Now Corporation (OTC: NWPN) looks poised to separate itself from all the rest... make sure you have the stock on your watchlist! Make sure you are ready to get all my alerts FAST by texting the word "Stocks" to "21000" (regular text messaging rates may apply) Also PLEASE take the time to read the following: ( I DO NOT MAKE ANY RECOMMENDATIONS TO BUY OR SELL ANY STOCKS, I JUST PROFILE COMPANIES AND YOU DECIDE WHAT TO DO) Placing a Trade First and foremost, you should always have streaming Level II quotes when trading. I honestly do not know how anyone trades without it! When trading, please follow the below guidelines: Always use a Limit Order: Most brokers won’t even allow you to use Market Orders. Limit Orders allow you to set the price that you want to buy and sell the stock at. This is common knowledge however, you may see some novice traders make the mistake of placing a market order to sell and take out all buyers at the bid, effectively overselling the stock to lower prices. Buy and Sell at the Ask: Many don’t realize that when you buy at the Ask price, you are HELPING the stock price to move up! Once that offer is gone from the shares you purchased, Market Makers could move up to the next offer price as they will see there are buyers at the current price. If you decide to place an order at the bid, you are basically hoping someone will sell their shares to you at this price and you may never get filled and miss the action. It is not always a bad idea to bid sit, as you are creating “bid support”, if you believe the price may come down again and you are not willing to buy higher. Using Stop Limit Orders: Some brokers do not allow you to use stops, however, if you can – it is always a good idea to set your stop loss at the lowest price you are willing to take a loss. You may kick yourself when the stock moves back up and your stop already executed, but remember, there will always be other opportunities and its always best to cut your losses just in case. All or None Orders (Fill or Kill): An example of an all or none order is when someone places an order to buy 100,000 shares @ .01 as an “all or none limit” order. By doing this they are telling the market that they wish to be filled on their entire position at .01 or not to be filled at all. For some reason we have seen market makers ignore these sort of orders on many occasions especially when a stock is on the move. We suggest against it but you will ultimately make the decision. Do Not Chase (ONE OF THE MOST IMPORTANT): Many people want to buy a stock so badly that they end up chasing the stock as it goes up. When they finally fill their order, they may have purchased it too high as traders who bought shares earlier begin to take profit, effectively lowering the stock price and making you a bag holder. Remember, 90% of the time, a stock will always retrace/dip back to an attractive level for you to grab shares. Stock Gaps: If a stock gaps up too high in pre-market, do Not Chase It. A big gap is typically 20-50% or more pre- market or within the first 5-10 minutes of the market opening. Most stocks that gap up will come down again during the day depending on what created the catalyst. Buying is always the catalyst but every once in a while there is earthshattering news on some of these small caps that makes pullbacks unlikely in the short term. Most of the time, when a stock gaps up the market makers will attempt to push it lower starting at this time to try to get investors to panic and sell shares back to them so they can make a profit on any shares they are short from filling orders on the gap. If you like the stock and it gaps up you can usually pick up cheaper shares when and if the market settles back. Sell Into Strength Not Weakness: Once you have taken a position in a stock you need to decide the price you would like to sell your shares. Most would recommend that you put a GTC sell order at that price. Unfortunately as traders have learned to utilize level 2, its best not to do submit GTC sell orders due to the possibility that your order will be represented by a market maker and it will seem as if there is resistance at that level which may compel sellers to get out of their position at a price lower than your price. We suggest that you watch the stock closely and once it hits your price target you can submit your order to sell. It’s important to understand that it’s always best to liquidate the stock into strength and preferably in smaller increments if you have a big position. There you have it!! These are ALL my biased, amateur and unlicensed opinions, should YOU choose freely, knowingly and intelligently to Play ANY of my featured play's!! (Please READ my statement below as well, it will help you understand how I benefit from this newsletter) Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99% of the time all that matters is HOW THE STOCK TRADES. If a stock doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book profits quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the stock is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book profits quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions) I would like to also explain how my Newsletter Makes MONEY!! I DON’T FRONTLOAD, BUY, RECEIVE any SHARES of a Company I Profile!! I NEVER OWN ANY POSITION IN A COMPANY I ALERT/PROFILE!! It would be UNFAIR, WRONG and ILLEGAL for me to have a position in ANY Company I ever Profile on my Newsletter! I am what is known as a STOCK PROMOTER!! I just wanted to address this issue for some people who might think I trade the companies I profile on my Newsletter or I own a position before or during the time I profile them!!! The honest truth is I DO NOT!!….. I do get CASH compensation to profile companies most of the times I talk about them in my Newsletter, this is HOW I MAKE MONEY and pretty much how 99% of ALL the other Newsletters out there make money…… Most of you have signed up to my Newsletter because of an advertisement you saw, well it costs money to run those advertisements…. I ALWAYS Disclose how much and who paid me in my Disclaimer at the end of each e-mail!!! Here is some information directly from the SEC Website: Tips for Checking Out Newsletters “Find out whether the newsletter received payment to “tout” or recommend the stock and, if so, what it received and from whom. Because the U.S. Constitution’s First Amendment protects freedom of speech, the SEC cannot simply prohibit newsletters from recommending or touting particular stocks. But when newsletters receive payment for touting, the securities laws require them to disclose specifically who paid them, the amount, and the type of payment (cash, stock, or some other thing of value). Read carefully what the newsletter says about payments it receives. Be suspicious of newsletters that do not specifically disclose these items: who paid them, the amount, and the type of payment. The following examples raise red flags because they do not contain specific information: “From time to time, XYZ Newsletter may receive compensation from companies we write about.” “From time to time, XYZ Newsletter or its officers, directors, or staff may hold stock in some of the companies we write about.” “XYZ Newsletter receives fees from the companies we write about in our newsletter.” Think twice about newsletters that bury their disclosures or put them in tiny, hard-to-read typeface. Legitimate online newsletters that have been paid to tout stocks will clearly and specifically tell investors who paid them, the amount, and the type of payment. Look for their disclosure statements in articles about particular companies or in a list or chart on their websites.” I hope this answers a lot of your questions and also gives you a better perspective to my play’s the Next Time you see one!! Don’t forget to tell everyone you know about PTE.la and help my Newsletter Grow!! Remember to trade smart, research your options, and use due diligence! Sincerely, PTE.la © 2020 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has been compensated up to Twenty-Five Thousand Dollars Cash by a third party Electrik Dojo to conduct investor relations advertising and marketing for NWPN. Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( [Change subscriber options](